IVVD
Invivyd, Inc.2.3800
+0.1600+7.21%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
659.41MP/E (TTM)
-Basic EPS (TTM)
-0.45Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
Q3 FY2025 results
Invivyd posted solid Q3 revenue of $13.1M from PEMGARDA sales, up 41% y/y from $9.3M yet flat q/q (derived), with gross margins approaching 80% if pre-EUA costs were capitalized. Operating loss narrowed to $11.0M from $62.3M y/y, driven by slashed R&D spend on VYD2311 manufacturing and pemivibart trials, while SG&A ticked up on headcount. YTD revenue hit $36.2M, 213% y/y growth, with net loss at $41.4M versus $151.5M last year; diluted EPS improved to $(0.30) from $(1.28), reconciling to 136.9M weighted shares. Cash stood at $85.0M, bolstered by $53.5M from August equity raise, but no debt drawn under the $30M facility. Pipeline advances with VYD2311's IND clearance and REVOLUTION trials slated for year-end. Revenue hinges on sustained COVID demand.
8-K
Invivyd Q3 revenue up 41%
Invivyd reported Q3 2025 PEMGARDA net product revenue of $13.1 million, up 41% year-over-year and 11% quarter-over-quarter, while slashing R&D expenses to $8.0 million from $57.9 million amid trial wind-downs. Cash swelled to over $100 million by October after an August $57.5 million public offering and October ATM proceeds. FDA cleared the IND for VYD2311, kicking off the REVOLUTION trials by year-end for mid-2026 data. Revenue climbs steadily.
8-K
Invivyd advances VYD2311 trials
Invivyd unveiled its investor presentation on October 30, 2025, spotlighting the REVOLUTION clinical program for VYD2311, a next-gen monoclonal antibody targeting COVID-19 pre-exposure prophylaxis. Phase 1/2 data showed clean safety at high doses up to 4500 mg IV, with mild reactions only. The Phase 3 DECLARATION trial aims for 70-90% risk reduction via single 250 mg IM dose over three months in broad populations. VYD2311's engineered stability counters viral evolution, yet regulatory hurdles loom.
ADMA
ADMA Biologics Inc
19.17-0.56
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
BIVI
BioVie Inc.
1.43+0.00
IBIO
iBio, Inc.
2.06+0.23
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
IVA
Inventiva S.A. - American Depos
4.66+0.18
IVBXF
Innovent Biologics Inc.
10.55+0.00
NVAX
Novavax, Inc.
6.54-0.04
REVB
Revelation Biosciences, Inc.
0.98+0.02
VIR
Vir Biotechnology, Inc.
6.48-0.24